Piramal Pharma Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/SNSE
₹239.30
-0.35-0.15% (1D)
As on 20 Nov 2026 at 15:57
As of 20 Nov 2026 at 15:57, Piramal Pharma Ltd is trading at ₹239.30. The 52-week range stands at ₹132.30–₹253.90, with a market cap of ₹31.85 thousand crore. At a P/E of 42.57 and a dividend yield of 0.00%, it is a large-cap stock in the Pharmaceuticals sector.

PPLPHARMA Price Chart

Market Cap
₹31.85K Cr
PE Ratio
42.57
ROCE
11.36%

Piramal Pharma Ltd Performance

Piramal Pharma Ltd Fundamentals

Know More
Market Cap₹31.85K Cr
ROE8.86%
P/E Ratio (TTM)42.57
EPS (TTM)₹5.62
P/B Ratio3.77
Dividend Yield0.00%
Industry P/E91.72
Book Value₹63.50
Debt to Equity0.07
Face Value₹10

Piramal Pharma Ltd Shareholding Pattern

Know More
Promoter34.8%
Foreign Institutions13.7%
Mutual Funds12.7%
Domestic Institutions1.7%
Public37.1%

Piramal Pharma Ltd Financial Statements

Know More
No data for this view.

Piramal Pharma Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Piramal Pharma

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company with the ROC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands. Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. The global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions. In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL). In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA). In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs. On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Enterprises Limited, Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to Company, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of the Company) into Company; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL became effective from August 18, 2022. In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paid-up value of Rs 10 each of the Company for every 1 equity share of face and paid-up value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited 'NSE) on October 19, 2022. In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023. In FY24, Company launched 27 new products and 24 new SKUs ; launched 21 new products and 31 new SKUs in FY 2025. The Company commenced manufacturing lines at Digwal to supplement Sevoflurane manufacturing capacity at Bethlehem (US) in FY 2025. The Company expanded capacity at Dahej and commissioned new Sevoflurane production lines at Digwal in FY26. It acquired Kenalog from Bristol Myers Squibb during 2026.

Parent Organisation—
Founded2020
Managing Director—
NSE SymbolPPLPHARMA

Piramal Pharma Ltd Resistance and Support levels

R3244.26R2242.12R1240.79S1236.50S2235.17S3233.02239.30

Piramal Pharma Ltd Technicals

Current Price
₹239.30 ₹0.35 (-0.15%)
Bearish
4
Bullish
8
  • 20 Day2.6%
  • 50 Day8.7%
  • 100 Day15.2%
  • 200 Day21.6%

Piramal Pharma Ltd Latest News

View More
28 OCT 2026 | Wednesday
Volumes spurt at Piramal Pharma Ltd counter
28 OCT 2026 | Wednesday
Piramal Pharma Ltd up for third consecutive session
28 OCT 2026 | Wednesday
Piramal Pharma Ltd leads gainers in 'A' group
16 OCT 2026 | Friday
Piramal Pharma to review quarterly results at board meeting on October 27, 2026
30 SEPT 2026 | Wednesday
Piramal Pharma appoints Viral Gandhi as CTO, effective October 1, 2026
30 SEPT 2026 | Wednesday
Brian Guy will lead Piramal Critical Care as President and COO starting October 19, 2026
29 SEPT 2026 | Tuesday
Piramal Pharma shutters securities trading for insiders pending financial results in late 2026
21 SEPT 2026 | Monday
Piramal Pharma Ltd up for third straight session
16 SEPT 2026 | Wednesday
Piramal Pharma Ltd drops for fifth straight session
28 AUG 2026 | Friday
Piramal Pharma Ltd rises for third straight session

2026

Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Piramal Pharma Ltd is ₹239.30 as of 20 Nov 2026 at 15:57.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now